Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more
Rezolute Inc (RZLT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.118x
Based on the latest financial reports, Rezolute Inc (RZLT) has a cash flow conversion efficiency ratio of -0.118x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.43 Million) by net assets ($147.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rezolute Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Rezolute Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Rezolute Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rezolute Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Entravision Communications Corporation
F:EV9
|
0.106x |
|
S IMMO AG
VI:SPI
|
0.019x |
|
Eurocell plc
PINK:ECELF
|
0.178x |
|
Dexterra Group Inc
PINK:HZNOF
|
0.148x |
|
Patel Engineering Limited
NSE:PATELENG
|
0.097x |
|
Ranhill Holdings Ltd
KLSE:5272
|
0.153x |
|
BRT Realty Trust
NYSE:BRT
|
0.049x |
|
Vine Hill Capital Investment Corp. Unit
NASDAQ:VCICU
|
0.071x |
Annual Cash Flow Conversion Efficiency for Rezolute Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Rezolute Inc from 2012 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $162.13 Million | $-69.08 Million | -0.426x | +10.13% |
| 2024-06-30 | $121.00 Million | $-57.37 Million | -0.474x | -23.82% |
| 2023-06-30 | $116.17 Million | $-44.48 Million | -0.383x | -44.46% |
| 2022-06-30 | $149.47 Million | $-39.62 Million | -0.265x | +66.16% |
| 2021-06-30 | $26.10 Million | $-20.44 Million | -0.783x | +76.13% |
| 2020-06-30 | $7.37 Million | $-24.17 Million | -3.281x | +62.43% |
| 2019-06-30 | $1.75 Million | $-15.30 Million | -8.735x | -345.15% |
| 2018-06-30 | $-3.96 Million | $-14.11 Million | 3.563x | +328.28% |
| 2017-06-30 | $8.53 Million | $-13.31 Million | -1.561x | -30.56% |
| 2016-06-30 | $8.77 Million | $-10.49 Million | -1.196x | -52.91% |
| 2015-06-30 | $9.05 Million | $-7.08 Million | -0.782x | -58.15% |
| 2014-06-30 | $6.41 Million | $-3.17 Million | -0.494x | -226.40% |
| 2013-06-30 | $-4.16 Million | $-1.63 Million | 0.391x | -94.76% |
| 2012-06-30 | $-5.41K | $-40.40K | 7.462x | -- |